Robeco Institutional Asset Management B.V. Raises Stock Holdings in Exelixis, Inc. $EXEL

Robeco Institutional Asset Management B.V. raised its position in Exelixis, Inc. (NASDAQ:EXEL) by 50.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 910,849 shares of the biotechnology company’s stock after buying an additional 305,320 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.33% of Exelixis worth $40,146,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EXEL. Hemington Wealth Management lifted its stake in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 522 shares during the last quarter. Byrne Asset Management LLC increased its holdings in shares of Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares during the period. Family Legacy Financial Solutions LLC acquired a new position in shares of Exelixis in the second quarter valued at approximately $33,000. Bartlett & CO. Wealth Management LLC acquired a new position in shares of Exelixis in the first quarter valued at approximately $37,000. Finally, Costello Asset Management INC acquired a new position in shares of Exelixis in the first quarter valued at approximately $39,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Exelixis stock opened at $40.09 on Friday. The firm has a market capitalization of $10.79 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 0.85 and a beta of 0.38. Exelixis, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $49.62. The stock’s fifty day moving average is $38.57 and its two-hundred day moving average is $39.85.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.Exelixis’s revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Saturday, September 27th. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. Stephens raised Exelixis from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $29.00 to $60.00 in a report on Tuesday, June 24th. The Goldman Sachs Group began coverage on Exelixis in a report on Wednesday, September 17th. They issued a “buy” rating and a $47.00 target price on the stock. Finally, UBS Group set a $38.00 price objective on Exelixis and gave the stock a “neutral” rating in a report on Wednesday, July 30th. Fifteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.42.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.